Solid Pharmaceutical Composition for Azetidin-3-ol Tablet Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or its salt that is excellent in dissolvability and moldability, and stable during long-term preservation, as existing formulations face issues with low compression moldability, sticking during tableting, and insufficient stability under high humidity conditions.
Innovation Solution
A solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or its salt combined with mannitol, sorbitol, or isomaltose, along with a disintegrant like croscarmellose sodium and a lubricant such as magnesium stearate, which enhances dissolvability and stability, and can be formulated into tablets using methods like dry granulation or direct tableting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Compound A or its salt is used as an oral formulation, then it provides neuroprotective and nerve regeneration effects, but it exhibits low compression moldability and proneness to tableting troubles such as sticking
Solution Approach 1:
The patent introduces a specific excipient composition containing microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate as intermediary materials to mediate between Compound A's poor compressibility and the tableting process requirements. This excipient blend acts as a bridge that enables proper tablet formation without compromising the active ingredient's therapeutic properties
Solution Approach 2:
The invention creates a composite powder mixture combining Compound A with specific ratios of multiple excipients (microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate). This composite material approach leverages the complementary properties of each component to achieve both manufacturability and therapeutic efficacy
2Ease of operation
If the mixed powder for tableting has low compression moldability, then Compound A can be administered orally, but the resulting tablets have insufficient hardness and are prone to damage during packaging and transportation
Solution Approach 1:
The excipient mixture serves as a mediating system that transfers and distributes compression force uniformly throughout the tablet, with microcrystalline cellulose providing structural framework and colloidal silicon dioxide enhancing particle bonding, thereby achieving adequate hardness while maintaining oral administrability
3Strength
If crystalline cellulose is blended to produce mixed powder with high compression moldability, then tablets achieve necessary hardness, but dissolvability and stability under preservation conditions of heating and moisturizing are insufficient
Solution Approach 1:
The patent changes the physical and chemical parameters of the excipient system by selecting microcrystalline cellulose with specific characteristics and combining it with colloidal silicon dioxide and magnesium stearate in optimized ratios. This parameter optimization achieves both adequate hardness and improved stability under various preservation conditions including heating and moisturizing
Solution Approach 2:
The invention employs a composite excipient system where microcrystalline cellulose provides structural integrity, colloidal silicon dioxide enhances moisture resistance and stability, and magnesium stearate prevents sticking. This composite approach delivers both mechanical strength and preservation stability simultaneously
4Ease of manufacture
If Compound A is formulated with lactose and crystalline cellulose, then tablets can be produced, but dissolvability and stability under preservation conditions require improvement
Solution Approach 1:
The patent optimizes the excipient parameters by replacing or supplementing conventional excipients with microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate in specific ratios. This parameter optimization simultaneously improves dissolvability through better particle characteristics and enhances stability under preservation conditions
Data Source
AI summary
This solid pharmaceutical composition is useful as a solid pharmaceutical composition of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol, which is excellently elutable and moldable and is stable in long-term storage, or a salt thereof.